Vilon is the name the St. Petersburg research literature uses for the dipeptide lysine-glutamate (Lys-Glu, or KE).1,2 The Khavinson and Anisimov report of 2000 in Doklady Biological Sciences is titled "A synthetic dipeptide vilon (L-Lys-L-Glu) inhibits growth of spontaneous tumors and increases life span of mice", and its PubMed record lists Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology.1 The 2021 systematic review by Khavinson and colleagues, from the same institute, describes the KE peptide as one "which is part of the drug Thymalin".2 The app files Vilon as a peptide bioregulator, lists the subcutaneous route, and grades its evidence as limited. The app's own notes describe the evidence as almost entirely from a single Russian research group with little independent replication. Khavinson is a listed author of the 2000 mouse lifespan report, the 2002 microarray study, the 2005 cancer-patient report and the 2021 review described below.6,3,8,2 A search of PubMed and ClinicalTrials.gov identified two reports typed as clinical trials, both in Russian-language gerontology literature (2005 and 2007), and no registered trial.

The sources below describe cell, animal and computer-modelling findings; none of them measures a mechanism in people.

The 2021 review by Khavinson and colleagues proposes that short peptides act on gene expression, writing that "Short peptides, consisting of 2-7 amino acid residues, can penetrate into the nuclei and nucleoli of cells and interact with the nucleosome, the histone proteins, and both single- and double-stranded DNA".2 The review's authors declare no conflict of interest and report no external funding, and the group that wrote it is the group that studied Vilon.2 For the KE dipeptide the review cites a molecular-modelling analysis in which KE "showed the best binding parameters to the TCGA dsDNA sequence among all the free-end dipeptides", and says that "in an in vitro study, the KE peptide regulated the expression of this gene" (APG5L).2 It also states that "AEDG and KE peptides were found to regulate the expression of 98 and 36 genes, respectively".2 A microarray study in mouse heart by Anisimov and colleagues (Bulletin of Experimental Biology and Medicine, 2002) counted clones rather than genes: of 15,247 clones, 300 changed expression "more than by 2 times"; "Vilon changed expression of 36 clones, while Epithalon modulated expression of 98 clones".3 The review does not name the report behind its figures of 98 and 36 genes.2 In that study Vilon alone or with Epithalon "activated expression of 157 clones (maximally by 6.13 times) and inhibited expression of 23 clones (maximally by 2.79 times)", and the authors conclude that the results "demonstrate the specific effects of Epithalon and Vilon on gene expression".3 Its PubMed record gives no dose, route, group size or funding statement.3

Caputi and colleagues (International Journal of Immunopathology and Pharmacology, 2019) tested KE, KED, AED and AEDG, alone and as a mixture, on human periodontal ligament stem cells in culture.4 In the PubMed summary, GAP43 "demonstrated an increased expression in hPDLSCs cultured with a compound of all studied peptides and with KED alone"; the results text reports that immunofluorescence showed AEDG, KE, AED, KED and their mixture increasing GAP43 synthesis versus control cells, and that the western blot showed the mixture and KED affecting GAP43 expression, in cultured cells.4 The paper reports that "The author(s) received no financial support for the research, authorship, and/or publication of this article" and "declared no potential conflicts of interest", and lists Khavinson V as its last of eight authors.4

In rats, Koplik and colleagues (Russian Physiological Journal, 2002) report that intraperitoneal vilon "inhibits hypertrophy of the adrenals, involution of the thymus, and elevates concentration of albumin in the blood plasma" in a stress model.5 This was a male Wistar rat study that Khavinson co-authored.5

3

Half-life and pharmacokinetics

Values from the Milligram app's model.

Half-life
~0.5 h
Bioavailability
90%
Typical dose
1–5 mg/day
Route
SubQ
Time to peak
~0.5 h

Sources in this part

  1. 6Khavinson et al., 2000

The second column of the table holds the app's own figures; the third column states what the sources contain.

Table 3.1Half-life and pharmacokinetics6 rows
ParameterApp's figureReported in the sources
Half-lifeAbout 0.5 hNo half-life of Vilon in people or animals was identified in the PubMed records retrieved
Bioavailability90%No bioavailability measurement was identified
Time to peakAbout 0.5 hNo time-to-peak measurement was identified
Duration6 hNone of the records retrieved reports a duration of effect in hours
RouteSubQSubcutaneous administration to female CBA mice in the 2000 lifespan study6
ModelOne-compartmentThe app does not list an absorption rate constant or volume of distribution; neither is reported in the records retrieved

None of the records retrieved gives a half-life, so there is no reported figure to set beside the app's 0.5 hours, and a level chart is not drawn.

4

Human studies

The searches identified two reports typed as clinical trials in PubMed. Both appear in the Russian journal Advances in Gerontology. Neither PubMed record gives a number of patients, a dose, a duration, effect sizes with intervals, a funding statement or adverse events.7,8

Table 4.1Human studies2 rows
Study and yearDesignPeopleDose and lengthMain result
Kuznik and colleagues, Advances in Gerontology 20077Clinical trial by PubMed type; Vilon added to complex therapy; comparator and randomisation not stated7Elderly patients with type I diabetes mellitus; number not stated7Not stated7Authors report Vilon "resulted in optimization of coagulation hemostasis" and "In most cases Vilon reduced the dose of insulin necessary for the stabilization of carbohydrate metabolism"; adverse events not reported7
Ias'kevich and colleagues, Advances in Gerontology 20058Controlled clinical trial by PubMed type; Vilon added to the treatment scheme; comparator not described8Elderly patients with stage III rectal and colon cancer; number not stated8Not stated8Authors call the results "preliminary" and write that they suggest "to increase 2-year survival of patients"; no figures or adverse events in the record8

Deeper analysis: Kuznik 2007, Vilon in elderly patients with type I diabetes

Kuznik, Isakova, Kliuchereva, Maleeva and Pinelis reported the study in Advances in Gerontology in 2007, and PubMed types it as a clinical trial.7 The PubMed title refers to "patients of different age with diabetes mellitus", while the summary text names elderly patients with type I diabetes mellitus.7 The authors state that the work "was aimed at the study of the effect of thymomimetic Vilon on the immune status and coagulation hemostasis in elderly patients with type I diabetes mellitus".7 Vilon was given "as an addition to the complex therapy" for this group.7 The reported coagulation findings were "the increased content of natural anticoagulants: antithrombin III and protein C, as well as in the stimulation of fibrinolysis".7 For immune measures the record states that "The content of T-helpers, T-dependent and non-T-dependent NK cells was reduced, and the level of active T-lymphocytes, B-lymphocytes and IgA was normalized".7 The insulin finding is worded "In most cases Vilon reduced the dose of insulin necessary for the stabilization of carbohydrate metabolism", with no count of cases given.7 The PubMed record states no number of patients, comparison group, dose, duration, p-values, null results, adverse events, authors' limitations, funding or ties to a manufacturer, and lists no affiliations for the authors.7

Deeper analysis: Ias'kevich 2005, Vilon with cancer treatment in elderly patients

Ias'kevich, Krutilina, Kostetskaia, Ryzhak and Khavinson reported the study in Advances in Gerontology in 2005; PubMed types it as a clinical trial and a controlled clinical trial.8 The authors describe "pioneer experience in complex radical treatment of elderly cancer patients with immunomodulator Vilon included into the scheme of treatment", in "stage III rectal and colon cancer".8 They write that the "obtained preliminary results of investigation suggest recommendation of Vilon application to increase 2-year survival of patients", for "prevention of post-operative complications, remote complications, recurrences and tumor dissemination", and for improvement of quality of life, without giving figures.8 The PubMed record gives no survival figures, patient numbers, comparison group, dose, duration, adverse events, funding or ties to a manufacturer, and lists no affiliations; the authors' own word for the findings is "preliminary".8

Animal studies (not human)

In the 2000 mouse lifespan study (Khavinson and colleagues, Bulletin of Experimental Biology and Medicine), subcutaneous Vilon given to female CBA mice from the 6th month of life "increased physical activity and endurance, decreased body temperature, prolonged the lifespan".6 The same record reports that "Vilon had no effect on age-related changes of estrous function and free radical processes".6 The record gives no group sizes, dose, funding statement or stated limitations; the authors conclude that the results "allow to use this preparation for geroprotection and prophylaxis of age pathology", a conclusion about mice that the PubMed record does not support with a human measurement.6 In a separate 2000 Doklady report the title states that vilon "inhibits growth of spontaneous tumors and increases life span of mice", and PubMed holds no summary for that record.1 In a rat bladder-tumor model induced with N-butyl-N-(4-hydroxybutyl)nitrosamine, Pliss and colleagues (2001) report that "The tumors developed in 56% vilon-treated animals and in 75.5% controls".9 In a mouse model induced with 1,2-dimethylhydrazine, Pliss and colleagues (Voprosy Onkologii, 2005) report that after 10 microg/kg "tumors developed in 14.3% which survived until first tumor detection (46 weeks)" against tumors in 60% of controls.10 Ivanov and colleagues (Advances in Gerontology, 2005) report in rats exposed to low-dose gamma radiation and mercury that Vilon "led to the normalization of the lymphocytes number by the 30th day", while "the number of granulocytes in the test group was higher than that in the intact control group".11 The same report states that "Vilon reduced morbidity of rats in the course of 15 months after RMI".11 The three reports above by Pliss and colleagues and Ivanov and colleagues were published in the Bulletin of Experimental Biology and Medicine, Voprosy Onkologii and Advances in Gerontology, Khavinson is a listed author on each, and none of their PubMed records states a funder.9,10,11

The safety statement located in the searches comes from mice: "Long-term administration of vilon caused no unfavourable effects on animal development".6 The two human reports give no adverse event data in their PubMed records, so no human adverse event rate can be stated.7,8

6

Bloodwork and markers

The app lists no health markers to monitor for Vilon. The diabetes report measured antithrombin III, protein C, fibrinolysis, T-helper cells, NK cells, active T-lymphocytes, B-lymphocytes, IgA and the insulin dose, and the rat radiation report counted lymphocytes and granulocytes.7,11

7

Regulatory and anti-doping status

The text of the WADA 2026 Prohibited List retrieved does not name Vilon, Lys-Glu or a dipeptide of that kind.12 Its S0 class reads: "Any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use".12 The class text continues with examples (drugs under pre-clinical or clinical development or discontinued, designer drugs, substances approved only for veterinary use) and states that such a substance is "prohibited at all times".12 The list names BPC-157 as an example in that class, and does not say whether the class applies to Vilon.12 A DailyMed search for "vilon" returned 0 labels, and a ClinicalTrials.gov search for "vilon peptide" returned 0 studies.

No pharmacokinetic study of Vilon was identified for the query "vilon pharmacokinetics" in PubMed, and the ClinicalTrials.gov query "vilon peptide" and the DailyMed query "vilon" returned 0 results; the searches were not run for dose-finding studies, placebo-controlled trials or replication. The app's half-life, bioavailability, time to peak and dose range of 1 to 5 mg/day have no reported figure beside them in the material retrieved. The human reports leave patient numbers, comparison groups, doses, durations and adverse events unstated in their PubMed records.7,8 Whether the gene-expression and DNA-binding findings described in the review occur in people at any dose is not addressed in the sources.2

What is Vilon?

Vilon is the name used in the Khavinson group's papers for the dipeptide Lys-Glu.1 The app lists the synonyms vilon, lys-glu and khavinson dipeptide.

What is the half-life of Vilon?

The app lists a half-life of about 0.5 hours. None of the records retrieved gives a half-life for Vilon, so there is no reported figure to set beside it.

Is Vilon banned by WADA?

The 2026 WADA Prohibited List text retrieved does not name Vilon.12 Its S0 class covers substances with no current approval by any governmental regulatory health authority for human therapeutic use, and the list does not say whether it applies to Vilon.12

Does Vilon have a DailyMed label or a registered trial?

A DailyMed search for "vilon" returned 0 labels and a ClinicalTrials.gov search for "vilon peptide" returned 0 studies.

Has Vilon been studied in people?

Two reports typed as clinical trials were identified in PubMed, one in elderly patients with type I diabetes (2007) and one in elderly patients with stage III rectal and colon cancer (2005).7,8 Their PubMed records give no patient numbers, doses or adverse events.7,8

Has Vilon been studied in animals?

Yes, in mice and rats, in reports on lifespan, tumor incidence, stress and low-dose radiation.6,9,5,11 The 2000 mouse report also states that "Vilon had no effect on age-related changes of estrous function and free radical processes".6

Is Vilon the same as Thymalin?

The 2021 review describes the KE peptide as one "which is part of the drug Thymalin", so the two names are related but not the same.2

Who has studied Vilon?

The reports found come largely from the St. Petersburg Institute of Bioregulation and Gerontology and Khavinson, who is a listed author on most of them.1,2

11

References

  1. Khavinson VKh, Anisimov VN. A synthetic dipeptide vilon (L-Lys-L-Glu) inhibits growth of spontaneous tumors and increases life span of mice. Dokl Biol Sci 2000. PMID 10944717
  2. Khavinson VK, Popovich IG, Linkova NS, Mironova ES, Ilina AR. Peptide Regulation of Gene Expression: A Systematic Review. Molecules 2021. PMC8619776
  3. Anisimov SV, et al. Studies of the effects of Vilon and Epithalon on gene expression in mouse heart using DNA-microarray technology. Bull Exp Biol Med 2002. PMID 12360356
  4. Caputi S, et al. Effect of short peptides on neuronal differentiation of stem cells. Int J Immunopathol Pharmacol 2019. PMC6376556
  5. Koplik EV, et al. Effect of dipeptide vilon on emotional stress resistance in rats. Ross Fiziol Zh Im I M Sechenova 2002. PMID 12587272
  6. Khavinson VK, et al. Effect of vilon on biological age and lifespan in mice. Bull Exp Biol Med 2000. PMID 11140587
  7. Kuznik BI, et al. Effect of vilon on the immunity status and coagulation hemostasis in patients of different age with diabetes mellitus. Adv Gerontol 2007. PMID 18306698
  8. Ias'kevich LS, et al. Application of peptide bioregulator in complex treatment of elderly cancer patients. Adv Gerontol 2005. PMID 16075684
  9. Pliss GB, et al. Inhibitory effect of peptide vilon on the development of induced rat urinary bladder tumors in rats. Bull Exp Biol Med 2001. PMID 11586406
  10. Pliss GB, et al. The effect of vilon (Lys-Glu) on 1.2-dimethylhydrazine-induced neoplasia. Vopr Onkol 2005. PMID 16308980
  11. Ivanov SD, et al. Vilon effect on consequences of repeated radioactive and mercuric impact in small doses. Adv Gerontol 2005. PMID 16075682
  12. World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. WADA list